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Abstract
Background: Drug-resistant tuberculosis (DR-TB) is considered a real threat to the achievement of TB control. Testing of
mycobacterial culture and testing of drug susceptibility (DST) capacity are limited in resource-poor countries, therefore
inadequate treatment may occur, favouring resistance development. We evaluated the molecular assay GenoType® MTBDRplus
(Hain Lifescience, Germany) in order to detect DR-TB directly in clinical specimens as a means of providing a more accurate
management of chronic TB patients in Burkina Faso, a country with a high TB-HIV co-infection prevalence.
Methods: Samples were collected in Burkina Faso where culture and DST are not currently available, and where chronic cases
are therefore classified and treated based on clinical evaluation and sputum-smear microscopy results. One hundred and eight
chronic TB patients (sputum smear-positive, after completing a re-treatment regimen for pulmonary TB under directly observed
therapy) were enrolled in the study from December 2006 to October 2008. Two early morning sputum samples were collected
from each patient, immediately frozen, and shipped to Italy in dry ice. Samples were decontaminated, processed for smear
microscopy and DNA extraction. Culture was attempted on MGIT960 (Becton Dickinson, Cockeysville, USA) and
decontaminated specimens were analyzed for the presence of mutations conferring resistance to rifampin and isoniazid by the
molecular assay GenoType® MTBDRplus.
Results: We obtained a valid molecular test result in 60/61 smear-positive and 47/47 smear-negative patients.
Among 108 chronic TB cases we identified patients who (i) harboured rifampin- and isoniazid-susceptible strains (n 24), (ii) were
negative for MTB complex DNA (n 24), and (iii) had non-tuberculous mycobacteria infections (n 13). The most represented
mutation conferring rifampin-resistance was the D516V substitution in the hotspot region of the rpoB gene (43.8% of cases).
Other mutations recognized were the H526D (15.6%), the H526Y (15.6%), and the S531L (9.4%).
All isoniazid-resistant cases (n 36) identified by the molecular assay were carrying a S315T substitution in the katG gene. In 41.7%
of cases, a mutation affecting the promoter region of the inhA gene was also detected.
Conclusion: The GenoType® MTBDRplus assay performed directly on sputum specimens improves the management of chronic
TB cases allowing more appropriate anti-TB regimens.
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Emergence of drug-resistant Mycobacterium tuberculosis
(MTB) strains is considered a real threat to achieving
tuberculosis (TB) control [1-3]. Furthermore, multidrug-
resistant TB (MDR-TB) and extensively drug-resistant TB
(XDR-TB) require prolonged and expensive chemother-
apy, with a decreased cure rate [4-6].
As diagnosis of MDR- and XDR-TB is based on mycobac-
terial culture and drug susceptibility testing (DST) on liq-
uid or solid media – with results available within weeks to
months [7-9] – inadequate treatment as well as further
spread of resistant strains and development of super-
resistance are likely to occur. Furthermore, standardized
and optimised MTB culture and DST procedures require
equipped, safe laboratories and trained human resources
operating under quality assurance protocols. For all of
these reasons, mycobacterial culture and DST capabilities
are severely limited in resource-poor countries.
In response to the growing problem of MDR-TB and the
threat of an epidemic of XDR-TB, the STOP TB strategy has
been revised to include universal access to diagnosis and
treatment for all patients with MDR-TB by 2015 [10,11].
This plan calls for accelerated access to rapid testing for
rifampin (RIF) resistance in order to improve case detec-
tion in all patients with suspected MDR- and XDR-TB. To
ensure universal access, new technologies for rapid detec-
tion of anti-TB drug resistance in MTB have become a pri-
ority, especially in settings with high HIV-prevalence [12-
15]. Early detection of MDR-TB and XDR-TB is critical to
initiating appropriate treatment, reducing morbidity and
mortality, and preventing further transmission of drug-
resistant MTB strains.
Although rapid molecular methods are available for
detecting drug-resistant TB [13,14,16], the feasibility and
cost-effectiveness of large-scale implementation in high-
burden low-income settings need to be assessed.
Demonstration projects on the GenoType® MTBDRplus
assay (Hain Lifesciences GmbH, Nehren, Germany), a
polymerase chain reaction (PCR) amplification and
reverse hybridization assay which detects RIF and isoni-
azid (INH) resistance, have been conducted in a high-bur-
den low-income country [17]. This assay detects
mutations in the rpoB gene for RIF resistance, and in both
the katG gene and the promoter region of the inhA gene
for INH resistance, directly from smear-positive sputum
within one day [18].
We evaluated the GenoType® MTBDRplus, a reverse
hybridization line probe assay for which detects DR-TB
directly in clinical specimens as a means to provide with
the purpose of providing more effective management of
chronic TB patients in Burkina Faso, a country with a high
TB-HIV co-infection prevalence [19].
Methods
Study settings
Samples were collected in Burkina Faso, a country in West
Africa with an estimated population of 14.9 million, and
an estimated incidence of TB (all forms) of 248/100.000
[19]. In 2008, the prevalence of HIV infection in TB
patients in Burkina Faso was 12.4% with a prevalence of
HIV among adult population estimated to be 1.6%
[20,21].
Culture and DST are not currently available in Burkina
Faso and chronic TB cases are classified and treated based
on clinical evaluation and sputum smear microscopy
results.
The work described in this paper was performed in the
framework of the agreement for technical support
requested by the National Tuberculosis Programme
(NTP) of Burkina Faso (responsible body for TB manage-
ment in the Country) to the Supranational Reference at
the San Raffaele Institute, Milan, Italy and the University
of Brescia, Italy. The NTP of Burkina Faso didn't consider
ethical approval to be necessary since this action was rec-
ommended by the Green Light Committee in order to
provide better management to chronic TB patients. All
patients were informed and consented to the study with
the local physicians.
The NTP has now prioritized the establishment of culture
and DST facilities by 2009 and rapid testing by 2010.
Clinical samples
One hundred and eight patients who met the definition of
"chronic pulmonary TB" ("patient who remained sputum
smear-positive after completing a re-treatment regimen
for pulmonary TB under Directly Observed Therapy
(DOT)", [22]) were started on a second line drug regimen
using a standardised treatment strategy (Category IV)
[23]. The Category IV drug regimen used in Burkina Faso
consists of kanamycin, ofloxacin, ethionamide, pyrazina-
mide and cycloserine for six months, followed by 15
months of ofloxacin, ethionamide and cycloserin.
Patients were enrolled at the two centres for chronic TB
patient management in Burkina Faso (Ouagadougou and
Bobo-Dioulasso) from December 2006 to October 2008.
Sixty-one patients were enrolled at the beginning of a Cat-
egory IV regimen (Month 0, M0). Forty-seven patients
were enrolled at variable times during their Category IV
therapy. Twenty-six out the 47 patients enrolled duringPage 2 of 8
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ative (Figure 1). Two early morning sputum samples were
collected from each patient at enrolment into the study,
immediately frozen and shipped to Italy in dry ice.
Upon arrival, samples were decontaminated and proc-
essed for smear microscopy and DNA extraction. Culture
was attempted on MGIT960 (Becton Dickinson, Cockeys-
ville, USA) automated system in agreement with the man-
ufacturer's instructions.
Molecular DST
Decontaminated specimens were analyzed for presence of
mutations conferring resistance to RIF and INH by the
molecular assay GenoType® MTBDRplus.
DNA from decontaminated clinical specimens was
extracted by thermal lysis and sonication and GenoType®
MTBDRplus assay was performed in accordance with the
manufacture's instructions with minor modifications (as
specified below). In brief, 500 μL of decontaminated sam-
ple were centrifuged at 13000 rpm at 4°C for 15 minutes;
pellet was resuspended in 75 μL of sterile distilled water
and mycobacteria were lysed by incubation at 95°C for 30
minutes and sonication for 15 minutes. Five microliters of
lysate were used for amplification with the provided bioti-
nylated primers. Two units (instead of 1 as reported in
manufacturer's instructions) of hot-start Taq DNA
polymerase were used in the amplification step. The
amplification was performed in a BioRad iCycler (BioRad,
Hercules, CA) thermal cycler with a protocol consisting of
1 cycle at 95°C for 15 min (Taq activation cycle), 10 cycles
of denaturation at 95°C for 30 sec and primer annealing
at 58°C for 2 min, 40 cycles of denaturation at 95°C for
25 sec, primer annealing at 53°C for 40 sec and extension
at 70°C for 40 sec, followed by a final extension at 70°C
for 8 min.
The GenoType® MTBDRplus is based on reverse hybridiza-
tion between amplicons derived from a multiplex PCR
and nitrocellulose-bound wild-type (WT) and mutated
(MUT) probes targeting the hotspot region of rpoB gene,
the codon 315 of katG gene and the promoter region of
inhA gene. The assay also includes amplification controls
for each targeted gene, an additional probes for gram-pos-
itive GC rich organisms, and a control-probe for MTB
complex DNA detection. Hybridisation and washing were
performed manually using the TWINCUBATOR® Hybridi-
Culture and GenoType® MTBDRplus results in patients enrolled at different times under category IV regimensFigure 1
Culture and GenoType® MTBDRplus results in patients enrolled at different times under category IV regi-
mens. The diagram reports smear microscopy results after the re-testing of samples in Italy and M. tuberculosis Complex 
results by GenoType MTBDRplus® and microbiology analyses. Patients are divided in two groups on the basis of the enrolment 
time in the study (beginning of the therapy, M0; during follow-up, M1–M30). The percentage of resistant cases as "any resist-
ance" is also reported (R).Page 3 of 8
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were interpreted for susceptibility or resistance to RIF and
INH according to manufacturer's instructions.
Results
The GenoType® MTBDRplus test was performed on all
samples regardless of the sputum smear results. Twenty-
one samples out of the 61 enrolled at M0 were not recon-
firmed as sputum smear-positive (Figure 1). We obtained
a valid test result (based on the hybridisation of the inter-
nal controls of the assay) in 60/61 smear-positive and 47/
47 smear-negative samples (Table 1).
Sputum smear-positive sample analysis
Out of 61 samples reconfirmed as positive and tested (40
at M0 and 21 collected during therapy), 46 cases were
found positive for MTB DNA confirming an active or past
disease. Twenty nine out of 46 (63.0%) were identified as
MDR by GenoType® MTBDRplus test. The percentage
increased to 67.4% when two cases identified as RIF
monoresistant were included. Eleven samples showed a
molecular profile suggestive of a TB strains susceptible to
both RIF and INH and 4 showed only mutations associ-
ated with INH resistance. Fourteen samples resulted MTB
Table 1: GenoType® MTBDRplus assay results obtained from sputum smear-positive and smear-negative chronic tuberculosis patients, 
Burkina Faso
Recruitment‡ (no.) Smear (no) GenoType® MTBDRplus Microbiology
MTB Complex result* (%) DST result† no. (%) Culture DST result† no. (%)
M0 (61) Positive (40) Positive (32) MDR 20 (32.8) MTB Complex MDR 18 (29.5)
MTB Complex RIF-S, INH-R 2 (3.2)
RIF-S, INH-R 3 (4.9) MTB Complex RIF-S, INH-R 2 (3.2)
Negative - 1 (1.6)
RIF-R, INH-S 1 (1.6) MTB Complex MDR 1 (1.6)
RIF-S, INH-S 8 (13.1) MTB Complex RIF-S, INH-S 7 (11.4)
M. simiae - 1 (1.6)
Negative (8) - 8 (13.1) M. avium - 3 (4.9)
Other NTM - 2 (3.2)
Negative - 3 (4.9)
Negative (21) Positive (11) RIF-S, INH-R 1 (1.6) Negative - 1 (1.6)
RIF ind, INH-S 1 (1.6) Negative - 1 (1.6)
RIF-S, INH-S 9 (14.8) MTB Complex RIF-S, INH-R 1 (1.6)
M. intracellulare - 1 (1.6)
Negative - 7 (11.4)
Negative (10) - 10 (16.4) M. avium - 2 (3.2)
M. intracellulare - 1 (1.6)
Negative - 7 (11.4)
Follow-up (47) Positive (21) Positive (14) MDR 9 (19.1) MTB Complex MDR 7 (14.9)
MTB Complex RIF-S, INH-R 1 (2.1)
Negative - 1 (2.1)
RIF-R, INH-S 1 (2.1) MTB Complex MDR 1 (2.1)
RIF-S, INH-R 1 (2.1) Negative - 1 (2.1)
RIF-S, INH-S 3 (6.4) MTB Complex RIF-S, INH-R 1 (2.1)
Negative - 2 (4.3)
Negative (6) - 6 (12.8) M. avium - 1 (2.1)
M. intracellulare - 1 (2.1)
Other NTM - 1 (2.1)
Negative - 3 (6.4)
Ind (1) - 1 (2.1) MTB Complex RIF-S, INH-S 1 (2.1)
Negative (26) Positive (6) MDR 1 (2.1) M. avium - 1 (2.1)
RIF-S, INH-R 1 (2.1) Nocardia spp. - 1 (2.1)
RIF-S, INH-S 4 (8.5) Negative - 4 8.5)
Negative (20) - 20(42.6) M. avium - 1 (2.1)
Other NTM - 1 (2.1)
Negative - 18 (38.3)
* MTB Complex, Mycobacterium tuberculosis Complex.
† DST, Drug susceptibility testing; MDR, Multidrug-resistant; RIF-S, Rifampin susceptible; RIF-R, Rifampin resistant; INH-S, Isoniazid susceptible; 
INH-R, Isoniazid resistant; ind, indeterminate
‡ M0, month 0; Follow-up, from month 1 to month 30.Page 4 of 8
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expected amplification result.
Liquid cultures were attempted from all the sputum
smear-positive samples. Forty out of 46 samples positive
for MTB DNA grew a TB strain, 1 grew a non-tuberculous
mycobacteria (NTM, M. simiae) and 5 resulted negative.
Analysis of the line probe assay test from those 6 cases
showed absence of mutations conferring resistance to RIF
in 3 of them (including the NTM case), one MDR case,
and two INH monoresistant patients. These last cases was
after 3 months after the beginning of the therapy with cat-
egory IV regimen.
Further testing on the isolated strains by DST performed
on MGIT960 confirmed 25 out of 29 MDR cases previ-
ously recognized by molecular test and also identified as
MDR the 2 RIF monoresistant cases. Three MDR cases at
the molecular test were INH monoresistant by DST.
Sequencing analysis of these strains allowed characteriza-
tion of all the mutations within the hotspot region of rpoB
gene (M515I+H526N, L533P, and H526N respectively).
Fourteen samples showed a GenoType® MTBDRplus test
negative for MTB complex probe, and in 8 cases the corre-
sponding cultures grew an NTM strain.
Sputum smear-negative samples analysis
Despite the fact that we did not re-confirm as smear-posi-
tive 21 patients enrolled at M0, we included these samples
in the molecular analysis. Twenty-six patients enrolled
during therapy and resulting smear-negative were also
included in the study (Table 1).
We obtained a GenoType® MTBDRplus test positive for
MTB complex DNA in 17/47 samples (36.2%); 13 of
them didn't show any mutations on the test (27.8%), 1
sample resulted MDR and 2 showed mutations associated
with resistance to INH. In one case the molecular test
resulted indeterminate for the rpoB gene.
Positive mycobacterial cultures were obtained from 3/17
(17.6%) samples; one grew MTB complex (monoresistant
to INH) and two of them grew NTMs (M. avium, M. intra-
cellulare). Two samples identified as INH mono-resistant
by the molecular assay resulted to be a culture-negative
and a Nocardia spp. strain, respectively.
The MTBDRplus resulted negative for presence of MTB
DNA in the remaining 30 samples (63.8%), from five
samples we cultured NTMs (3 M. avium, 1 M. fortuitum, 1
M. intracellulare).
Frequency of mutations
Frequency of mutations in MTB complex positive samples
identified as resistant to RIF and/or INH by the MTBDR-
plus assay are summarized in Table 2. Concerning smear-
positive samples, amongst the 31 RIF-R detected cases, the
most represented mutation is the D516V substitution in
the hotspot region of rpoB gene, involved in resistant phe-
notype in 41.9% (13/31) of cases. Other mutations recog-
nized were H526D (16.1%, 5/31), H526Y (16.1%, 5/31),
and S531L (9.7%, 3/31), respectively. In 16.1% (5/31) of
cases, resistance to RIF was identified by the lack of
hybridization for WT probes in the analyzed region of
rpoB gene. Two of them were confirmed as RIF-R by DST.
Three cases bearing the following mutations in rpoB
(M515I+H526N, L533P, and H526N respectively)
resulted RIF-S by DST and were further investigated. Min-
imum inhibitory concentration (MIC) evaluation was
performed on the strains. The two strains harbouring
L533P and H526N, respectively, despite resulting RIF sus-
ceptible, showed a slight increase in the MIC value (0.5
μg/mL). The strain carrying the 515I+H526N substitu-
tions showed a MIC of 2 μg/mL.
Concerning INH resistance, all cases identified by the
molecular assay (n 33) were carrying a S315T substitution
in katG gene. In 39.4% (13/33) of cases, a mutation affect-
ing the promoter region of inhA gene was also detected.
Observed frequency of mutation in this region was 21.2%
(7/33) t-8c, 12.1% (4/33) t-8a, and 6.1% (2/33) c-15t,
respectively. In 20 out of 33 cases (60.6%) no mutation
was identified in the promoter region of inhA gene.
Frequency of mutations observed in sputum smear-nega-
tive samples are also reported in Table 2.
Discussion
Conventional methods for mycobacteriological culture
and DST are slow and labour intensive, requiring sequen-
tial procedures for isolation of mycobacteria from clinical
specimens, identification of MTB complex, and in vitro
testing of strain susceptibility to anti-TB drugs. During this
time patients may be prescribed inadequate treatment,
thus fuelling the development and/or spread of drug
resistance. Novel technologies for rapid detection of anti-
TB drug resistance have therefore become a priority in TB
research and development, and molecular line probe
assays focused on rapid detection of RIF resistance (alone
or in combination with INH) are now commercially avail-
able.
In June 2008, concomitantly with the first published
meta-analysis on MTBDR line probe assays [24], WHO
has made public the policy statement on molecular line
probe assays for rapid screening of patients at risk of
MDR-TB [25]. However, adoption of line probe assays
does not eliminate the need for conventional culture and
DST capability, as culture remains necessary for definitive
diagnosis of TB in sputum smear-negative patients, while
conventional DST of second line drugs is required to diag-Page 5 of 8
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for patient follow-up during treatment.
The aim of our study was to evaluate the molecular assay
GenoType® MTBDRplus for detecting DR-TB directly in
sputum specimens as a means to provide a more accurate
management of chronic TB patients in Burkina Faso. Our
study demonstrates that the GenoType® MTBDRplus assay
can be used to identify MDR-TB cases correctly in the
absence of culture facilities in TB patients classified as
"chronic" according to internationally accepted criteria.
Moreover, this study strongly suggests that sputum smear-
microscopy as the only criteria to identify chronic TB
patients is inadequate because of the risk of false positives.
The use of the GenoType® MTBDRplus molecular test, with
further confirmation from culture and DST, allowed read-
justment of patients' treatment in over half of the cases
studied: 1) patients who were classified and treated as
MDR-TB cases harbouring RIF- and INH-S strains (n 24);
2) patients negative for MTB complex DNA among those
enrolled at M0 or remaining smear-positive during fol-
low-up (n 24); 3) patients with a NTM infection (n 13). In
addition, the correct classification of patients allowed to
reconsider their need for hospitalization in MDR-TB
wards limiting nosocomial exposure to MDR-TB.
The GenoType® MTBDR plus assay performed directly on
clinical specimens is less expensive than culture-based
DST. We recommend that cost-effectiveness in applying
the test should be carefully evaluated in each setting tak-
ing into account specific situations (e.g. TB and HIV prev-
alence), technical skills available on site, and frequency of
mutations among resistant samples to evaluate the sensi-
tivity of the molecular assay.
More data is needed to validate the use of molecular
assays for rapid detection of drug resistance to key anti-TB
drugs such as RIF and INH under routine conditions.
Our study found that the GenoType® MTBDR plus yielded
interpretable results in more than 99% of the cases,
among both smear-positive and smear-negative sputum
samples.
Reported sensitivities for RIF- and INH- resistance for the
GenoType® MTBDR plus are ≥ 97% and ≥ 90%, respec-
tively [24]. Also specificities are accounted to be ≥ 99% for
both RIF- and INH- resistances. In our study, 4 samples
showed INH susceptibility by molecular line probe assay,
while these were identified as INH-resistant by culture
based DST. A possible explanation is the lower sensitivity
of the test on INH resistance since the GenoType® MTBDR
Table 2: MTBDRplus-detected mutation frequency for RIF-R and INH-R on 63 MTB complex-positive samples, Burkina Faso
Smear result (no.) GenoType® MTBDRplus
Drug susceptibility testing result rpoB katG inhA no. (%)
Positive (46) MDR D516V S315T(1) t-8c 5 (10.8)
D516V S315T(1) t-8a 2 (4.3)
D516V S315T(1) wt 5 (10.8)
H526D S315T(1) wt 4 (8.7)
H526D S315T(2) wt 1 (2.2)
H526Y S315T(1) t-8c 2 (4.3)
H526Y S315T(1) t-8a 1 (2.2)
H526Y S315T(1) wt 2 (4.3)
S531L S315T(1) c-15t 1 (2.2)
S531L S315T(1) wt 1 (2.2)
No wt 3–4–7 S315T(1) c-15t 1 (2.2)
No wt 7 S315T(1) wt 3 (6.5)
No wt 8 S315T(1) wt 1 (2.2)
RIF-R, INH-S D516V wt wt 1 (2.2)
S531L wt wt 1 (2.2)
RIF-S, INH-R wt S315T(1) wt 3 (6.5)
wt S315T(1) t-8a 1 (2.2)
RIF-S, INH-S wt wt wt 11 (23.9)
Negative (17) MDR D516V S315T(1) c-15t 1 (5.8)
RIF-S, INH-R wt S315T(1) t-8a 1 (5.8)
wt S315T(1) wt 1 (5.8)
RIF indeter, INH-S indeter. wt wt 1 (5.8)
RIF-S, INH-S wt wt wt 13 (76.5)
* MDR, Multidrug-resistant; RIF-S, Rifampin susceptible; RIF-R, Rifampin resistant; INH-S, Isoniazid susceptible; INH-R, Isoniazid resistant; wt, wild-
type; indeter, indeterminate.Page 6 of 8
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in determining INH-resistance [26].
Three samples designated as MDR-TB by GenoType®
MTBDR plus assay, were not confirmed to be RIF resistant
on culture-based DST. Further investigation on these 3
cases identified mutations in the rpoB gene
(M515I+H526N, L533P, and H526N respectively). Dis-
crepancies between culture and molecular DST can be
interpreted by studying the MICs of the corresponding
strains. In fact, strains carrying the substitution L533P in
rpoB gene have been demonstrated to have different MIC
values (from 0.5–1.0 μg/mL up to 32 μg/mL) [27,28]. Fur-
ther evaluation on the three strains carrying substitutions
in rpoB gene allowed to identify increased MIC values.
Our study had several limitations. Discrepant results in
sputum smear microscopy in Burkina Faso and Italy could
be due to differences in the sampling time and in recruit-
ment of patients by peripheral centers with suboptimal
capacity in smear microscopy.
Discrepant GenoType® MTBDRplus-positive and culture-
negative samples may be justified in two ways. First, some
samples were collected and transported to Italy under sub-
optimal conditions and this may have affected their cul-
ture results [29]. Second, most of the culture-negative
samples harboured DNA from MTB susceptible strains by
GenoType® MTBDRplus. For these cases we speculate that
standard TB treatment was effective and prescription of
WHO Category IV regimen unnecessary.
One case with negative culture and with a positive MDR
profile on molecular assay may be due to the fact that this
case was sampled six months after the beginning of the
therapy with category IV regimen. In fact, we observed
during treatment follow-up that the molecular assay
became negative between month 3 and month 6 in
patients under effective treatment (data not shown).
Two sputum smear-negative samples harbouring NTM
(M. intracellulare, M. avium) were identified as MTB com-
plex positive by the GenoType® MTBDRplus. This may be
due to successful treatment that contributed to select
microorganisms not belonging to the MTB complex.
Results obtained in our sample suggest that in Burkina
Faso the frequency of mutations involved in RIF resistance
differs from that of other settings. The commonest muta-
tion is the D516V substitution in the hotspot region of
rpoB gene, detected entirely in 43.8% (14/32) of RIF resist-
ant cases. The S531L mutation is responsible of resistant
phenotype in only 9.4% (3/32) in our study, whereas this
substitution affects the majority of RIF resistant strains in
most of other countries worldwide [26]. In this study we
observed that mutations in the promoter region of inhA
gene had a minor role in conferring resistance to INH. As
these data were obtained from chronic patients undergo-
ing two cycles of standard first-line drugs regimen, we
believe that low-level resistance mutations have favoured
secondary selections for high-level resistance mutations
such as S315T substitution in the katG gene [30], and we
recommend further studies be conducted.
The molecular test correctly identifies as MTB-complex
negative all the patients in which the smear positivity was
probably due to the presence of NTMs as suggested by cul-
ture results. The addition of a Mycobacteria genus specific
probe could address this problem improving the clinical
usefulness of the test, especially in high HIV prevalence
settings.
As shown in other studies the molecular assay has been
successfully performed on contaminated cultures to
obtain drug susceptibility data [17]. This provides impor-
tant drug resistance data in settings where culture and cul-
ture DST testing are not conducted correctly as confirmed
by quality control systems.
Conclusion
In conclusion, our results demonstrate the usefulness of
the GenoType® MTBDR plus assay in identifying MDR-TB
cases (among patients satisfying the chronic TB defini-
tion), in the absence of culture facilities. The molecular
assay improved the management of chronic cases by offer-
ing timely access to more appropriate anti-TB regimens,
and this could limit the emergence of resistance due to the
misuse of antibiotics, and reduce public health expenses.
Guidelines and algorithms for line probe assays use
should be available to improve quality and cost-effective
use of molecular assays in TB control, and be specifically
evaluated in local settings. We recommend that an exter-
nal quality assurance system should exist for all laborato-
ries performing the test.
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